Antineoplastic chemotherapy induced pancytopenia
ICD-10 D61.810 is a billable code used to indicate a diagnosis of antineoplastic chemotherapy induced pancytopenia.
Antineoplastic chemotherapy induced pancytopenia is a hematological condition characterized by a reduction in red blood cells, white blood cells, and platelets due to the effects of chemotherapy agents used in cancer treatment. This condition arises when chemotherapy damages the bone marrow, leading to impaired hematopoiesis, which is the process of blood cell production. Patients may present with symptoms such as fatigue, increased susceptibility to infections, and bleeding tendencies due to low platelet counts. The severity of pancytopenia can vary based on the type and dosage of chemotherapy, as well as the patient's overall health and pre-existing conditions. Aplastic anemia, a form of bone marrow failure, can also be a consequence of chemotherapy, where the bone marrow fails to produce adequate blood cells. Acquired anemias, including those induced by antineoplastic agents, require careful monitoring and management, as they can significantly impact treatment plans and patient outcomes. Understanding the pathophysiology and clinical implications of chemotherapy-induced pancytopenia is crucial for effective management and coding.
Detailed records of chemotherapy regimens, lab results, and patient symptoms.
Patients undergoing chemotherapy who present with fatigue, infections, or bleeding.
Close monitoring of blood counts and timely documentation of any changes in the patient's condition.
Comprehensive patient history, including previous treatments and current symptoms.
Management of patients with multiple comorbidities and complications from chemotherapy.
Understanding the interplay between chemotherapy effects and other medical conditions.
Used to monitor blood counts in patients undergoing chemotherapy.
Document the reason for the CBC and any relevant symptoms.
Hematology specialists should ensure that the CBC results are correlated with clinical findings.
D61.810 is primarily caused by the effects of antineoplastic chemotherapy on bone marrow, leading to reduced production of blood cells.
Coders should ensure that documentation clearly links the diagnosis of pancytopenia to chemotherapy treatment and includes relevant lab results.
